- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03335176
Feasibility of Telerehabilitation in HIV-patients
Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients
The aim of this study is to assess the feasibility and the effects of a 6-week telerehabilitation on the three domains of the International Classification of Functioning, Disability and Health in HIV-infected patients under highly active antiretroviral therapy (HAART).
HIV-infected patients were randomized either into an Endurance and Resistance Training Exercise (ERTE) group or a control (CON) group. Telerehabilitation was realized in a public fitness center, with online guidance and weekly telephone advice, 3 times per week for 6 weeks. Feasibility was determined by recruitment rate, retention rate and adverse events. Secondary outcomes were impact on body composition, inflammation and coagulation (C-reactive protein, D-dimer), physical fitness and quality of life (WHOQOL-HIV).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years or older
- under HAART treatment
- native French speaker
Exclusion Criteria:
- AIDS diagnosis
- physical and/or psychiatric impairments that seriously impaired physical activity
- pregnant
- Unstable (defined by any modification of health outcomes during the last 6 months).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Kontrollgruppe
Vanlig omsorg
|
|
|
Eksperimentell: Endurance and Resistance Training Exercise
|
Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recruitment rate
Tidsramme: At study completion (after 6 weeks)
|
Number of eligible participants who enrolled in the program out of the number were recruited
|
At study completion (after 6 weeks)
|
|
Retention rate
Tidsramme: At study completion (after 6 weeks)
|
Percentage of patients lost to follow-up
|
At study completion (after 6 weeks)
|
|
Adverse events
Tidsramme: At study completion (after 6 weeks)
|
Percentage of patients who experienced one or more adverse events
|
At study completion (after 6 weeks)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Weight
Tidsramme: Assessments at baseline and at 6 weeks
|
Weight (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
|
Lean body mass
Tidsramme: Assessments at baseline and at 6 weeks
|
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
|
Fat body mass
Tidsramme: Assessments at baseline and at 6 weeks
|
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
|
C-reactive protein
Tidsramme: Assessments at baseline and at 12 weeks
|
C-reactive protein is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
|
D-dimer
Tidsramme: Assessments at baseline and at 12 weeks
|
D-dimer is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
|
CD4+ T cell counts
Tidsramme: Assessments at baseline and at 12 weeks
|
CD4+ T cell counts is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
|
Viral load
Tidsramme: Assessments at baseline and at 12 weeks
|
Viral load is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
|
Functional exercise capacity
Tidsramme: Assessments at baseline and at 6 weeks
|
Functional exercise capacity is measured by a 6-minute walk test
|
Assessments at baseline and at 6 weeks
|
|
Flexibility
Tidsramme: Assessments at baseline and at 6 weeks
|
Flexibility is measured by Toe touch test and sit and reach test
|
Assessments at baseline and at 6 weeks
|
|
Lower body muscular strength
Tidsramme: Assessments at baseline and at 6 weeks
|
Lower body muscular strength is measured by 30-s chair-stand test
|
Assessments at baseline and at 6 weeks
|
|
Upper limb strength
Tidsramme: Assessments at baseline and at 6 weeks
|
Upper limb strength is measured by hand grip strength tool
|
Assessments at baseline and at 6 weeks
|
|
Quality of life
Tidsramme: Assessments at baseline and at 6 weeks
|
Quality of life is measured by World Health Organization Quality of Life HIV Instrument
|
Assessments at baseline and at 6 weeks
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Sykdommer i immunsystemet
- Langsomme virussykdommer
- HIV-infeksjoner
- Ervervet immunsviktsyndrom
- Immunologiske mangelsyndromer
Andre studie-ID-numre
- Telerehabilitation HIV
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Humant immunsviktvirus
-
First Affiliated Hospital of Zhejiang UniversityHangzhou Suxi Biopharmaceutical Co., Ltd.Har ikke rekruttert ennåHIV (Human Immunodeficiency Virus)Kina
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)Har ikke rekruttert ennåHIV (Human Immunodeficiency Virus)Forente stater
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); Mbarara University of Science... og andre samarbeidspartnereRekruttering
-
Okan UniversityFullførtHIV (Human Immunodeficiency Virus)Tyrkia (Türkiye)
-
Okan UniversityFullførtHIV (Human Immunodeficiency Virus)Tyrkia (Türkiye)
-
Biogipuzkoa Health Research InstituteHar ikke rekruttert ennå
-
KC Care Health CenterHar ikke rekruttert ennå
-
Eswatini Nazarene Health InstitutionsBaylor Foundation EswatiniHar ikke rekruttert ennåHIV (Human Immunodeficiency Virus)Eswatini
-
Shanghai Public Health Clinical CenterBeijing Ditan Hospital; Peking Union Medical College Hospital; First Affiliated... og andre samarbeidspartnereHar ikke rekruttert ennåIRIS | HIV (Human Immunodeficiency Virus)
-
Rhode Island HospitalNational Institute of Mental Health (NIMH)Har ikke rekruttert ennåHIV (Human Immunodeficiency Virus) | Depresjonsforstyrrelser